CVE:DOC - CloudMD Software & Services Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$3.88
  • Forecasted Upside: 102.88 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$1.91
▼ -0.03 (-1.55%)

This chart shows the closing price for DOC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CloudMD Software & Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOC

Analyst Price Target is C$3.88
▲ +102.88% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CloudMD Software & Services in the last 3 months. The average price target is C$3.88, with a high forecast of C$4.25 and a low forecast of C$3.50. The average price target represents a 102.88% upside from the last price of C$1.91.

This chart shows the closing price for DOC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in CloudMD Software & Services. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/10/2021Canaccord GenuityLower Price TargetC$3.75 ➝ C$3.50
3/9/2021LaurentianBoost Price TargetC$4.00 ➝ C$4.25
2/1/2021LaurentianSet Price TargetBuyC$4.00
9/22/2020Canaccord GenuityBoost Price TargetC$1.75 ➝ C$2.50
9/1/2020Canaccord GenuityBoost Price TargetC$1.30 ➝ C$1.75
8/25/2020Canaccord GenuityBoost Price TargetC$1.20 ➝ C$1.30
7/7/2020Echelon Wealth PartnersReiterated RatingSpeculative Buy
(Data available from 7/25/2016 forward)
CloudMD Software & Services logo
CloudMD Software & Services Inc., a healthcare technology company, provides SaaS based health technology solutions to medical clinics in North America. It offers CloudMD telemedicine application, a telemedicine platform that connects patients to licensed physician through videoconferencing technology; operates a network of inter-connected medical clinics; and Re:Function, an integrated network of 8 rehabilitation clinics that offers various rehabilitation services. The company also retails prescription drugs, over-the-counter drugs, and other front store items through two pharmacies, as well as provides clinical services, such as medical reviews and compounding; and provides cloud-based electronic medical records (EMR) software, medical billing and practice management software, and various telemedicine platforms to medical professionals, as well as digital platforms to serve individuals for their eyecare and specialty drug needs. In addition, it offers JunoEMR, a cloud-based EMR solution; MyHealthAccess, an online patient portal for online appointment booking and telemedicine visits; Benchmark, a suite of cloud-based medical practice solutions; and ClinicAid, a medical billing software. Further, the company provides Livecare Connect, a telemedicine platform; IDYA4, a health data integration and security technology platform; VisionPros, an online eyecare platform that offers contact lenses and eyeglasses under the KIND brand; Rxi, a specialty drug wholesaler, pharmacy, and technology/patient support program administrator. Additionally, it provides enterprise health solutions, including mental health support; employee and student assistance programs; healthcare navigation and specialist; rehabilitation and assessments; education; and absence management. The company was formerly known as Premier Health Group Inc. and changed its name to CloudMD Software & Services Inc. in February 2020. The company was incorporated in 2013 and is headquartered in Victoria, Canada.
Read More

Today's Range

Now: C$1.91
Low: C$1.88
High: C$1.93

50 Day Range

MA: C$1.94
Low: C$1.74
High: C$2.32

52 Week Range

Now: C$1.91
Low: C$0.54
High: C$3.43

Volume

421,410 shs

Average Volume

1,278,687 shs

Market Capitalization

C$440.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CloudMD Software & Services?

The following Wall Street sell-side analysts have issued stock ratings on CloudMD Software & Services in the last twelve months: Canaccord Genuity, and Laurentian.
View the latest analyst ratings for DOC.

What is the current price target for CloudMD Software & Services?

2 Wall Street analysts have set twelve-month price targets for CloudMD Software & Services in the last year. Their average twelve-month price target is C$3.88, suggesting a possible upside of 102.9%. Laurentian has the highest price target set, predicting DOC will reach C$4.25 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of C$3.50 for CloudMD Software & Services in the next year.
View the latest price targets for DOC.

What is the current consensus analyst rating for CloudMD Software & Services?

CloudMD Software & Services currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DOC will outperform the market and that investors should add to their positions of CloudMD Software & Services.
View the latest ratings for DOC.

What other companies compete with CloudMD Software & Services?